These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

417 related articles for article (PubMed ID: 25532106)

  • 1. MicroRNA-7 inhibits multiple oncogenic pathways to suppress HER2Δ16 mediated breast tumorigenesis and reverse trastuzumab resistance.
    Huynh FC; Jones FE
    PLoS One; 2014; 9(12):e114419. PubMed ID: 25532106
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oncogenic HER2{Delta}16 suppresses miR-15a/16 and deregulates BCL-2 to promote endocrine resistance of breast tumors.
    Cittelly DM; Das PM; Salvo VA; Fonseca JP; Burow ME; Jones FE
    Carcinogenesis; 2010 Dec; 31(12):2049-57. PubMed ID: 20876285
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An oncogenic isoform of HER2 associated with locally disseminated breast cancer and trastuzumab resistance.
    Mitra D; Brumlik MJ; Okamgba SU; Zhu Y; Duplessis TT; Parvani JG; Lesko SM; Brogi E; Jones FE
    Mol Cancer Ther; 2009 Aug; 8(8):2152-62. PubMed ID: 19671734
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Downregulation of miR-342 is associated with tamoxifen resistant breast tumors.
    Cittelly DM; Das PM; Spoelstra NS; Edgerton SM; Richer JK; Thor AD; Jones FE
    Mol Cancer; 2010 Dec; 9():317. PubMed ID: 21172025
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Erythropoietin receptor expression and its relationship with trastuzumab response and resistance in HER2-positive breast cancer cells.
    Zhang C; Duan X; Xu L; Ye J; Zhao J; Liu Y
    Breast Cancer Res Treat; 2012 Dec; 136(3):739-48. PubMed ID: 23117856
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MiRNA‑542‑3p downregulation promotes trastuzumab resistance in breast cancer cells via AKT activation.
    Ma T; Yang L; Zhang J
    Oncol Rep; 2015 Mar; 33(3):1215-20. PubMed ID: 25586125
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The microRNA-21/PTEN pathway regulates the sensitivity of HER2-positive gastric cancer cells to trastuzumab.
    Eto K; Iwatsuki M; Watanabe M; Ida S; Ishimoto T; Iwagami S; Baba Y; Sakamoto Y; Miyamoto Y; Yoshida N; Baba H
    Ann Surg Oncol; 2014 Jan; 21(1):343-50. PubMed ID: 24154840
    [TBL] [Abstract][Full Text] [Related]  

  • 8. microRNA-133a regulates the cell cycle and proliferation of breast cancer cells by targeting epidermal growth factor receptor through the EGFR/Akt signaling pathway.
    Cui W; Zhang S; Shan C; Zhou L; Zhou Z
    FEBS J; 2013 Aug; 280(16):3962-74. PubMed ID: 23786162
    [TBL] [Abstract][Full Text] [Related]  

  • 9. miR-217 and CAGE form feedback loop and regulates the response to anti-cancer drugs through EGFR and HER2.
    Kim Y; Kim H; Park D; Han M; Lee H; Lee YS; Choe J; Kim YM; Jeoung D
    Oncotarget; 2016 Mar; 7(9):10297-321. PubMed ID: 26863629
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MicroRNA-7 expression in colorectal cancer is associated with poor prognosis and regulates cetuximab sensitivity via EGFR regulation.
    Suto T; Yokobori T; Yajima R; Morita H; Fujii T; Yamaguchi S; Altan B; Tsutsumi S; Asao T; Kuwano H
    Carcinogenesis; 2015 Mar; 36(3):338-45. PubMed ID: 25503932
    [TBL] [Abstract][Full Text] [Related]  

  • 11. EGFR over-expression and activation in high HER2, ER negative breast cancer cell line induces trastuzumab resistance.
    Dua R; Zhang J; Nhonthachit P; Penuel E; Petropoulos C; Parry G
    Breast Cancer Res Treat; 2010 Aug; 122(3):685-97. PubMed ID: 19859802
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacological blockade of fatty acid synthase (FASN) reverses acquired autoresistance to trastuzumab (Herceptin by transcriptionally inhibiting 'HER2 super-expression' occurring in high-dose trastuzumab-conditioned SKBR3/Tzb100 breast cancer cells.
    Vazquez-Martin A; Colomer R; Brunet J; Menendez JA
    Int J Oncol; 2007 Oct; 31(4):769-76. PubMed ID: 17786307
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Posttranscriptional upregulation of HER3 by HER2 mRNA induces trastuzumab resistance in breast cancer.
    Li X; Xu Y; Ding Y; Li C; Zhao H; Wang J; Meng S
    Mol Cancer; 2018 Aug; 17(1):113. PubMed ID: 30068375
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ErbB-2 inhibition activates Notch-1 and sensitizes breast cancer cells to a gamma-secretase inhibitor.
    Osipo C; Patel P; Rizzo P; Clementz AG; Hao L; Golde TE; Miele L
    Oncogene; 2008 Aug; 27(37):5019-32. PubMed ID: 18469855
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epigenetic silencing of miR-375 induces trastuzumab resistance in HER2-positive breast cancer by targeting IGF1R.
    Ye XM; Zhu HY; Bai WD; Wang T; Wang L; Chen Y; Yang AG; Jia LT
    BMC Cancer; 2014 Feb; 14():134. PubMed ID: 24571711
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MicroRNA-191, an estrogen-responsive microRNA, functions as an oncogenic regulator in human breast cancer.
    Nagpal N; Ahmad HM; Molparia B; Kulshreshtha R
    Carcinogenesis; 2013 Aug; 34(8):1889-99. PubMed ID: 23542418
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Modulation of MicroRNA-194 and cell migration by HER2-targeting trastuzumab in breast cancer.
    Le XF; Almeida MI; Mao W; Spizzo R; Rossi S; Nicoloso MS; Zhang S; Wu Y; Calin GA; Bast RC
    PLoS One; 2012; 7(7):e41170. PubMed ID: 22829924
    [TBL] [Abstract][Full Text] [Related]  

  • 18. miR-21: A gene of dual regulation in breast cancer.
    Zhang C; Liu K; Li T; Fang J; Ding Y; Sun L; Tu T; Jiang X; Du S; Hu J; Zhu W; Chen H; Sun X
    Int J Oncol; 2016 Jan; 48(1):161-72. PubMed ID: 26549725
    [TBL] [Abstract][Full Text] [Related]  

  • 19. miR-205-5p-mediated downregulation of ErbB/HER receptors in breast cancer stem cells results in targeted therapy resistance.
    De Cola A; Volpe S; Budani MC; Ferracin M; Lattanzio R; Turdo A; D'Agostino D; Capone E; Stassi G; Todaro M; Di Ilio C; Sala G; Piantelli M; Negrini M; Veronese A; De Laurenzi V
    Cell Death Dis; 2015 Jul; 6(7):e1823. PubMed ID: 26181203
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Calpain4 is required for activation of HER2 in breast cancer cells exposed to trastuzumab and its suppression decreases survival and enhances response.
    Kulkarni S; Saju L; Farver C; Tubbs R
    Int J Cancer; 2012 Nov; 131(10):2420-32. PubMed ID: 22377768
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.